| David M. Goldenberg Immunomedics, Inc. 
During the last decade, several antibodies have become commercialized for use in the areas of infectious disease,
auto-immune disease and cancer therapy, resulting in a new era of biological pharmaceuticals, and accounting for $10
billion in annual sales in the U.S. These biological agents are often safer and easier for patients to use than traditional
drugs.
Dr. David Goldenberg is one of the recognized pioneers in the use of monoclonal antibodies. He is President of the Garden State Cancer Center and the Center of Molecular Medicine and Immunology and is founder and Chairman of the Board of the publicly held biotechnology firm, Immunomedics, Inc. and its subsidiary, IBC Pharmaceuticals, Inc. He holds over 150 U.S. and foreign patents in the fields of disease imaging, monoclonal antibodies, use of antibody conjugates in therapy, anti-idiotype cancer and infectious disease vaccines and methods to overcome multi-drug resistance and myelotoxicity of radio-conjugates. Many of Dr. Goldenberg's patents are for products and methods that are currently in pre-clinical and clinical development. Two products that have already been approved are: CEA-Scan® for diagnostic imaging of cancer and LeukoScan® for diagnostic imaging of infection. Having been one of the first to gain patents in this new field, Dr. Goldenberg has generated much scientific and commercial interest, and received numerous awards and recognition for his pioneering work. He has written or co-authored approximately 1,400 journal articles, abstracts and book chapters on cancer immunology and cancer research, has served on the editorial boards for several respected medical journals and is an active member of many scientific societies. |
